chronic urticaria chronic urticaria butyrate UAS7
Conditions
Interventions
Oral Butyrate supplement 2400 mg , 600 mg/ capsule , 2 capsule after breakfast and dinner , duration 4 weeks ,Placebo 1 capsule after breakfast and dinner
Butyrate,Placebo
Sponsors
Department of Medicine of Phramongkutklao hospital
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: chronic urticaria patients who symptoms do not improve with second generation antihistamine drug
Exclusion criteria
Exclusion criteria: 1. History of butyrate allergy 2. Immunocompromised patient , psychiatric , kidney impairment and hepatic impairment patient 3. Patient need to take other medicine for chronic urticaria treatment other than second generation antihistamine drug eg. H2 antagonists , leukotriene receptor antagonists, first-generation antihistamine, cyclosporine or omalizumab 4. Pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of butyrate supplement in chronic urticaria treatment time at end of intervention Dermatology Life Quality Index (DLQI) and Urticaria activity score7 (UAS7) | — |
Secondary
| Measure | Time frame |
|---|---|
| Laboratory improvement in chronic urticaria patient after butyrate supplement time at end of intervention D dimer , CRP , dysfunctional Treg, basophil activation test | — |
Countries
Thailand
Contacts
Public ContactPatcharat Chiamruchikun
Allegy and Immunology of Internal Medicine, Phramongkutklao hospital
Outcome results
None listed